



Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQX: LVCLY

ASX ANNOUNCEMENT

Dr Andrew Kelly joins LCT board

7 November 2019 – Sydney, Australia & Auckland, New Zealand – At today's Annual General Meeting Dr Andrew Kelly was appointed to the board of Living Cell Technologies Limited (LCT) as a non-executive director, effective immediately.

Dr Kelly has an extensive background in research, commercialisation and investment. In 2005 he co-founded BioPacificVentures, the first specialist venture fund in New Zealand and Australia to focus across the life sciences. In 2014 he broadened the business model to create BioPacific Partners, partnering with some of the largest global companies to invest and engage with local innovation.

Dr Kelly spent the early part of his career in life sciences research and development in Australia and Canada and then led research institutes in Australia and New Zealand. He later led product development and then early stage investment at AgResearch. In this role he built deep engagement with the global investor community.

He has held a dozen board roles over the last 22 years all in businesses involved in life science innovation. Dr Kelly has strong networks across New Zealand and Australia and globally. He holds a PhD in Veterinary Science from the University of Melbourne, a MSc from the University of Saskatchewan and a BVSc (Hons) from the University of Melbourne.

"On behalf of the Board, I welcome Andrew," says LCT Interim Chairman Professor Bernie Tuch. "I look forward to working together with Dr Kelly and my other board colleagues to deliver the best outcomes for shareholders and patients."

Dr Kelly says, "As a long-term shareholder and believer in the LCT journey, I am honoured to be voted on to the Board. I look forward greatly to contributing new perspectives on direction and action to reach the company's long-held goals."

– Ends –

For further information: www.lctglobal.com

At the Company: Ken Taylor Chief Executive Mobile: +64 21 796 000 ktaylor@lctglobal.com	Media Contact: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz
---	---

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as its lead product NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter.